Nathan Fine - Cyclo Therapeutics Executive Chairman of the Board, CEO
Chairman
Mr. N. Scott Fine is Executive Chairman of the Board, Chief Executive Officer of the Company. From 2004 until 2014, Mr. Fine was a principal at Scarsdale Equities, an investment banking firm located in New York City. Mr. Fine currently sits on the Board of Directors of Kenon Holdings Ltd, a spinoff from Israel Corporation Ltd, and Forward Industries, where he serves as Lead Director. Mr. Fine is also Chairman of the Global Virus Network, a Board member of Operation Respect, and a Member of the Board of Trustees of the Imperial War Museum American Air Museum at Duxford, UK. Mr. Fine was a director of Central European Distribution Corporationrationration, a multibillion dollar alcohol beverage company, from 1996 until 2014, during which time he led the CEDC Board successful efforts in 2013 to restructure the company through a prepackaged Chapter 11 process whereby CEDC was acquired by the Russian Standard alcohol group. since 2015.
Age | 58 |
Tenure | 9 years |
Phone | 386 418 8060 |
Web | http://www.ctd-holdings.com |
Cyclo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (111.53) % which means that it has lost $111.53 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (601.41) %, meaning that it created substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 198.78 K in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Cyclo Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cyclo Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cyclo Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cyclo Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cyclo to invest in growth at high rates of return. When we think about Cyclo Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | CHAIRMAN Age | ||
William Daley | Bank of New | 70 | |
Manuel Pangilinan | P10 Inc | 71 | |
Curtis Arledge | Bank of New | 49 | |
Joseph Echevarria | Bank of New | 64 | |
Charles Scharf | Bank of New | 52 | |
Hani Kablawi | Bank of New | 52 | |
Brian Shea | Bank of New | 55 | |
Reginald Gillard | Perseus Mining Limited | 66 | |
Robert Alpert | P10 Inc | 59 | |
Stephen Angel | P10 Inc | 61 | |
W Reum | Waste Management | 72 | |
Thomas Weidemeyer | Waste Management | 73 | |
Gerald Hassell | Bank of New | 64 | |
Robert Reum | Waste Management | 72 | |
Thomas Gibbons | Bank of New | 64 | |
Robin Vince | Bank of New | 52 |
Management Performance
Return On Equity | -601.41 | |||
Return On Asset | -111.53 |
Cyclo Therapeutics Leadership Team
Elected by the shareholders, the Cyclo Therapeutics' board of directors comprises two types of representatives: Cyclo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclo. The board's role is to monitor Cyclo Therapeutics' management team and ensure that shareholders' interests are well served. Cyclo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Nathan Fine, Executive Chairman of the Board, CEO | ||
George Fails, Executive VP, Operations Manager, Director and Member of Nomination and Governance Committee | ||
Jeffrey Tate, CEO and President Director, Member of Audit Committee, CEO of Nanosonic Products Inc, CEO of Sphingo Biotechnology, Inc. and President of Nanosonic Products Inc and President of Sphingo Biotechnology, Inc | ||
William Shanahan, Director | ||
Scott Fine, Chairman, CEO, Chairman of Audit Committee and Chairman of Nomination and Governance Committee | ||
C Strattan, Director, Member of Compensation Committee and CEO of CTD, Inc. | ||
Markus Sieger, Director | ||
Joseph Farnan, Director | ||
Joshua Fine, CFO | ||
Sharon Hrynkow, Sr. VP for Medical Affairs and Member of Scientific Advisory Board | ||
Patrick Ostronic, Independent Director | ||
Randall Toig, Director |
Cyclo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cyclo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -601.41 | |||
Return On Asset | -111.53 | |||
Operating Margin | (905.22) % | |||
Current Valuation | 10.71 M | |||
Shares Outstanding | 169.98 M | |||
Shares Owned By Insiders | 1.20 % | |||
Shares Owned By Institutions | 0.21 % | |||
Price To Earning | (6.45) X | |||
Price To Book | 4.75 X | |||
Price To Sales | 10.87 X |
Pair Trading with Cyclo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclo Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Genworth Financial could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genworth Financial when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genworth Financial - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genworth Financial to buy it.
The correlation of Genworth Financial is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genworth Financial moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genworth Financial moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genworth Financial can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Cyclo Therapeutics information on this page should be used as a complementary analysis to other Cyclo Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Cyclo OTC Stock
If you are still planning to invest in Cyclo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclo Therapeutics' history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |